- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Management and grading of EGFR inhibitor-induced cutaneous toxicity. (Pubmed Central) - Apr 3, 2019 This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Aliqopa (copanlisib) / Bayer
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: COPAN-ORL06: Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (clinicaltrials.gov) - Apr 3, 2019 P1/2, N=11, Active, not recruiting, Trial completion date: Jul 2020 --> Dec 2021 | Trial primary completion date: Jan 2020 --> Dec 2021 Recruiting --> Active, not recruiting | N=32 --> 11 | Trial primary completion date: Nov 2017 --> Nov 2019
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Undifferentiated carcinoma of the oral tongue treated with cetuximab: A case report. (Pubmed Central) - Apr 2, 2019 The tumor's size decreased markedly after two courses of chemotherapy, but the treatment was stopped due to the patient' various mental problems and pneumonia; he died 6 months after the initial visit. Our encounter with this patient suggests that cetuximab treatment is a good option for HPV-positive undifferentiated carcinoma of the oral tongue.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. (Pubmed Central) - Mar 27, 2019 ...This unresponsiveness was mechanistically attributed to the loss of negative feedbacks on the epidermal growth factor receptor (EGFR) and initiated clinical trials that combine BRAF (and MEK) inhibitors, either singly or in combination, with the anti-EGFR antibodies cetuximab or panitumumab...Importantly, combination of the BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with inhibitors dually targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells...Furthermore, Gab2 and Gab2-mediated Shp2 signaling were shown to be functionally important in BRAFi resistance. These findings highlight potential new escape mechanisms to these targeted therapies and indicate that a broad suppression of RTK signaling might be beneficial and should be taken into account in future research addressing targeted therapy in BRAF-mutant CRC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. (Pubmed Central) - Mar 27, 2019 These findings highlight potential new escape mechanisms to these targeted therapies and indicate that a broad suppression of RTK signaling might be beneficial and should be taken into account in future research addressing targeted therapy in BRAF-mutant CRC. The results of our multicenter retrospective study, which was the largest of its kind to date, suggest that first-line cetuximab plus platinum-based chemotherapy is suitable and well-tolerated for the systemic therapy of recurrent or metastatic OSCC.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Clinical, Journal, IO Biomarker: Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer. (Pubmed Central) - Mar 25, 2019 By combination treatment with rhCD137L, similar effects were obtained regarding cancer cell cytotoxicity in the presence of cetuximab (p < 0.01)...These results confirmed that FcγRIIIA polymorphisms (158 V/V) enhanced CD137 expression to a greater degree than 158 F polymorphisms (p = 0.014). Our results suggested that CD137 stimulation could promote the effects of tumor-targeting mAbs in gastric cancer, and that further investigation of antibody binding affinity and in vivo activities might improve therapeutic strategies related to the treatment of gastric cancer patients.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: The KRAS Variant as a Predictive Biomarker of Cetuximab Response in Head and Neck Cancer. (Pubmed Central) - Mar 23, 2019 Our results suggested that CD137 stimulation could promote the effects of tumor-targeting mAbs in gastric cancer, and that further investigation of antibody binding affinity and in vivo activities might improve therapeutic strategies related to the treatment of gastric cancer patients. No abstract available
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: KESTREL: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 21, 2019 P3, N=823, Active, not recruiting, No CBOS was noted when D0.1cc was <47.6 Gy. Trial completion date: Dec 2018 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Sep 2019
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kisqali (ribociclib) / Novartis
Trial termination, Metastases: CETLEE011: Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (clinicaltrials.gov) - Mar 11, 2019 P1, N=21, Terminated, Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> Aug 2018 Active, not recruiting --> Terminated; Decided by the investigator due to the difficulties to recruit
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: NCI-2018-02990: Cetuximab in Head and Neck Cancer Patients (clinicaltrials.gov) - Mar 8, 2019 P2, N=36, Recruiting, Active, not recruiting --> Terminated; Decided by the investigator due to the difficulties to recruit Not yet recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Combination therapy, IO biomarker, Metastases: Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC (clinicaltrials.gov) - Mar 5, 2019 P2, N=39, Recruiting, Initiation date: Feb 2019 --> May 2019 Not yet recruiting --> Recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma
Enrollment change, Trial completion date, Trial withdrawal, Metastases: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 4, 2019 P1/2, N=0, Withdrawn, Not yet recruiting --> Recruiting N=22 --> 0 | Trial completion date: Dec 2016 --> Jul 2016 | Active, not recruiting --> Withdrawn
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Feb 26, 2019 P2, N=17, Active, not recruiting, N=22 --> 0 | Trial completion date: Dec 2016 --> Jul 2016 | Active, not recruiting --> Withdrawn Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021
- |||||||||| Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (clinicaltrials.gov) - Feb 20, 2019 P3, N=688, Recruiting, Trial completion date: May 2021 --> Sep 2020 | Trial primary completion date: Jan 2021 --> Jan 2019 Trial completion date: Jan 2021 --> Dec 2027 | Trial primary completion date: Oct 2019 --> Dec 2027
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial initiation date, Trial primary completion date: Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (clinicaltrials.gov) - Feb 20, 2019 P2, N=78, Recruiting, Trial completion date: Jan 2021 --> Dec 2027 | Trial primary completion date: Oct 2019 --> Dec 2027 Trial completion date: Oct 2021 --> Feb 2020 | Initiation date: Sep 2016 --> Sep 2015 | Trial primary completion date: Sep 2020 --> Feb 2020
- |||||||||| EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial completion date, Trial primary completion date, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Feb 12, 2019 P1, N=30, Active, not recruiting, This first-in-human study demonstrates the feasibility and safety of antibody based imaging for CE glioblastomas. Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jan 2019 --> Jan 2021
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: ACE-Lung: Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (clinicaltrials.gov) - Feb 12, 2019 P2, N=118, Active, not recruiting, N=30 --> 0 | Terminated --> Withdrawn Recruiting --> Active, not recruiting | N=170 --> 118 | Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Oct 2018 --> Feb 2019
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors (clinicaltrials.gov) - Feb 8, 2019 P1, N=15, Terminated, Not yet recruiting --> Recruiting N=22 --> 15 | Trial completion date: Jun 2019 --> Dec 2016 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Dec 2016; Primary investigator left the institution.
|